Sept 27 (Reuters) - Allergy Therapeutics PLC AGY.L :
* FY REVENUE FELL 16 PERCENT TO 61.0 MILLION STG
* FY REVENUE OF £61.0M (2022: £72.8M) FROM COMMERCIAL
PORTFOLIO
* SUBJECT TO TIMING AND VOLUME OF SALES IN QUARTER TO DEC
2023,
EXPECTS ADDITIONAL FUNDING TO BE REQUIRED FROM AROUND NOV 2023
ONWARDS
* PIVOTAL PHASE III GRASS G306 MATA MPL TRIALUNDERWAY AND ON
TRACK
TO REPORTINTERIM TRIAL RESULTS IN, OR AROUND, NOVEMBER 2023
Source text for Eikon: ID:nRSa7517Na
Further company coverage: AGY.L
((Reuters.Briefs@thomsonreuters.com;))